PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143397
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143397
CircRNA Synthesis Market size was valued at US$ 210.7 Million in 2025, expanding at a CAGR of 16.2% from 2026 to 2033.
CircRNA synthesis encompasses the design, in vitro transcription, circularization, purification, and quality control processes that contribute to the production of covalently closed RNA for research and therapeutic development. Unlike traditional linear RNA production, the workflow must control both the efficiency of circularization and the removal of uncircularized RNA, double-stranded RNA, truncated products, and other immunogenic impurities. Hence, the market also comprises synthesis instruments and reagents along with specialized custom production services to support protein expression, drug discovery, vaccines, gene therapy, and biomarker research. An integrated enzymatic and cellulose-based purification strategy has been demonstrated in a 2025 Advanced Science study to increase the yield of CircRNA manufacturing by more than 10-fold, as well as to reduce immune activation. This evidence shifts buying priorities to reproducible circularization, purity, analytical validation, and scalable workflows rather than just RNA generation.
CircRNA Synthesis Market- Market Dynamics
Demand for Higher Purity and More Scalable Circularization Workflows
The main manufacturing challenge is moving CircRNA from laboratory experiments to material that can be used in demanding translational studies. Traditional ligation and ribozyme methods can create limits on sequence, length, purification, and by-products, so process control becomes a differentiator. A 2025 Nature Communications study showed that chemical circularization works for RNA lengths from 35 to 4,000 nucleotides and that circularization efficiency can reach up to 60 percent, showing that synthesis research is expanding the design space. Meanwhile, researchers continue to stress scar-free designs and better impurity removal. The final requirement is not more CircRNA output; suppliers must now offer controllable circularization, flexible sequences, purification, and characterization as a single integrated production workflow. Process control must be maintained throughout. Suppliers must keep process control as a core focus.
The Global CircRNA Synthesis Market is segmented on the basis of Product Type, Application, End User, and Region.
By product type, product type segmentation shows how laboratories balance internal process control with technical expertise. Instruments matter when organizations need transcription, purification, chromatography, and analytical workflows. Reagents and kits provide access to enzymes, transcription components, ligation systems, and purification chemistry without building a whole platform. Services occupy a unique position because they transfer sequence design, circularization, purification, and quality control to specialist providers. GenScript, for example, offers three custom methods-PIE with a scarless PIE and scarless T4-ligation-covering both coding and non-coding uses. The commercial difference comes from who owns the workflow: advanced research groups can build processes while therapeutic developers increasingly prefer integrated production and characterization.
By application, application needs shift significantly when CircRNA moves from biology to therapeutic work. Drug discovery uses CircRNA to study protein expression, RNA function, target biology, and possible mechanisms. This creates a demand for sequence designs and rapid changes. Therapeutics development emphasizes purity, reproducibility, translation performance, immunogenicity, and delivery compatibility because manufacturing details can change downstream results. ClinicalTrials.gov listed a Phase I/II study using a circular RNA-derived tumor-antigen vaccine with 60 patients, with a planned start in December 2025. This move creates a manufacturing need in therapeutics development: CircRNA suppliers must link synthesis quality with application-specific biological checks instead of treating RNA production as a separate lab step.
CircRNA Synthesis Market- Geographical Insights
Asia Pacific has built a strong translational ecosystem around CircRNA, with China bringing together academic research, biotechnology advancement, and regulatory oversight. In January 2025, Shanghai CirCode Biomed announced that its HM2002 circular RNA therapeutic had received Investigational New Drug approval from China's NMPA. The company described this as the CircRNA therapeutic to receive such approval in China. The impact of this milestone goes beyond the HM2002 therapy itself. It signals a growing need for manufacturing, tight control over impurities, detailed analytical characterization, and scalable circularization techniques. China continues to advance synthesis research, including work in 2025 on scarless circularization and self-splicing systems. This region is not merely a consumer of CircRNA research; it is actively shaping the technology through both translational ambitions and innovation. The synergy between development and science makes Asia Pacific a key driver in the field.
North America's involvement in CircRNA is heavily influenced by the interplay among RNA technology providers, therapeutic developers, and U.S. regulatory processes. On May 30, 2025, CirCode announced that HM2002 had received FDA IND clearance for heart disease, expanding the therapy's regulatory journey beyond China. In another development, the FDA's orphan-designation database shows that a circular RNA therapy expressing hepatocyte growth factor was granted orphan designation on October 23, 2025, for thromboangiitis obliterans. These regulatory steps emphasize the need for quality therapeutic-grade synthesis and rigorous documentation. Key areas include identity verification, purity assessment, consistent production, and robust manufacturing controls. North America's role is central in moving CircRNA from lab-scale experiments to developed therapeutic programs. The market is shifting toward formalized production standards and analytical rigor, marking a transition from research-grade to development-ready CircRNA.
Competition is now distinguished by the ability to manage the CircRNA workflow instead of just providing RNA reagents. GenScript combines custom synthesis with several circularization methods and purification, while GENEWIZ from Azenta pushes a unique group I-intron workflow for high-quality circular RNA production. Creative Biolabs also integrates sequence design, circularization, purification, and validation that focuses on CircRNA applications. Technology developers compete by enhancing cellular performance and improving therapeutic outcomes. Circio states that in its 2025 report, the new circVec 4.0 platform boosted protein output by 50 percent over the earlier circVec 3.2 version. What this means for competition is a move toward process power designed for specific uses and clear performance metrics rather than merely the ability to make CircRNA.
In March 2025, researchers created a multi-step purification process that used enzymes and cellulose-based methods to remove the main immunogenic CircRNA by-products. After refining the process, they observed more than a ten-fold improvement in CircRNA production yield.
In July 2025, scientists introduced a chemical circularization technique for RNA made through in vitro transcription. This method was designed to expand the types of structures that can be built using chemical synthesis. It successfully produced chem-CircRNAs ranging from 35 to 4,000 nucleotides in length, achieving circularization efficiency as high as 60 percent.